BIOMAT Database Logo BIOMAT Database Logo

Neuropharmacological actions of cigarette smoke: brain monoamine oxidase B (MAO B) inhibition. 1998

J S Fowler, and N D Volkow, and G J Wang, and N Pappas, and J Logan, and R MacGregor, and D Alexoff, and A P Wolf, and D Warner, and R Cilento, and I Zezulkova
Department of Chemistry and Medicine, Brookhaven National Laboratory, Upton, NY 11973, USA.

We measured the concentration of brain monoamine oxidase B (MAO B; EC 1.4.3.4) in 8 smokers and compared it with that in 8 non-smokers and in 4 former smokers using positron emission tomography (PET) and deuterium substituted [11C]L-deprenyl ([11C]L-deprenyl-D2) as a radiotracer for MAO B. Smokers had significantly lower brain MAO B than non-smokers as measured by the model term lambda k3 which is a function of MAO B activity. Reductions were observed in all brain regions. Low brain MAO B in the cigarette smoker appears to be a pharmacological rather than a genetic effect since former smokers did not differ from non-smokers. Brain MAO B inhibition by cigarette smoke is of relevance in light of the inverse association between smoking and Parkinson's disease and a high prevalence of smoking in psychiatric disorders and in substance abuse. Though nicotine is at the core of the neuropharmacological actions of tobacco smoke, MAO B inhibition may also be an important variable in understanding and treating tobacco smoke addiction.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D008995 Monoamine Oxidase An enzyme that catalyzes the oxidative deamination of naturally occurring monoamines. It is a flavin-containing enzyme that is localized in mitochondrial membranes, whether in nerve terminals, the liver, or other organs. Monoamine oxidase is important in regulating the metabolic degradation of catecholamines and serotonin in neural or target tissues. Hepatic monoamine oxidase has a crucial defensive role in inactivating circulating monoamines or those, such as tyramine, that originate in the gut and are absorbed into the portal circulation. (From Goodman and Gilman's, The Pharmacological Basis of Therapeutics, 8th ed, p415) EC 1.4.3.4. Amine Oxidase (Flavin-Containing),MAO,MAO-A,MAO-B,Monoamine Oxidase A,Monoamine Oxidase B,Type A Monoamine Oxidase,Type B Monoamine Oxidase,Tyramine Oxidase,MAO A,MAO B,Oxidase, Monoamine,Oxidase, Tyramine
D008996 Monoamine Oxidase Inhibitors A chemically heterogeneous group of drugs that have in common the ability to block oxidative deamination of naturally occurring monoamines. (From Gilman, et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed, p414) MAO Inhibitor,MAO Inhibitors,Reversible Inhibitors of Monoamine Oxidase,Monoamine Oxidase Inhibitor,RIMA (Reversible Inhibitor of Monoamine Oxidase A),Reversible Inhibitor of Monoamine Oxidase,Inhibitor, MAO,Inhibitor, Monoamine Oxidase,Inhibitors, MAO,Inhibitors, Monoamine Oxidase
D009538 Nicotine Nicotine is highly toxic alkaloid. It is the prototypical agonist at nicotinic cholinergic receptors where it dramatically stimulates neurons and ultimately blocks synaptic transmission. Nicotine is also important medically because of its presence in tobacco smoke. Nicotine Bitartrate,Nicotine Tartrate
D001921 Brain The part of CENTRAL NERVOUS SYSTEM that is contained within the skull (CRANIUM). Arising from the NEURAL TUBE, the embryonic brain is comprised of three major parts including PROSENCEPHALON (the forebrain); MESENCEPHALON (the midbrain); and RHOMBENCEPHALON (the hindbrain). The developed brain consists of CEREBRUM; CEREBELLUM; and other structures in the BRAIN STEM. Encephalon
D002250 Carbon Radioisotopes Unstable isotopes of carbon that decay or disintegrate emitting radiation. C atoms with atomic weights 10, 11, and 14-16 are radioactive carbon isotopes. Radioisotopes, Carbon
D003903 Deuterium The stable isotope of hydrogen. It has one neutron and one proton in the nucleus. Deuterons,Hydrogen-2,Hydrogen 2
D005260 Female Females
D005947 Glucose A primary source of energy for living organisms. It is naturally occurring and is found in fruits and other parts of plants in its free state. It is used therapeutically in fluid and nutrient replacement. Dextrose,Anhydrous Dextrose,D-Glucose,Glucose Monohydrate,Glucose, (DL)-Isomer,Glucose, (alpha-D)-Isomer,Glucose, (beta-D)-Isomer,D Glucose,Dextrose, Anhydrous,Monohydrate, Glucose

Related Publications

J S Fowler, and N D Volkow, and G J Wang, and N Pappas, and J Logan, and R MacGregor, and D Alexoff, and A P Wolf, and D Warner, and R Cilento, and I Zezulkova
Inhibition of monoamine oxidase B (MAO-B) by Chinese herbal medicines.
November 2003, Phytomedicine : international journal of phytotherapy and phytopharmacology,
J S Fowler, and N D Volkow, and G J Wang, and N Pappas, and J Logan, and R MacGregor, and D Alexoff, and A P Wolf, and D Warner, and R Cilento, and I Zezulkova
Irreversible inhibition of monoamine oxidase by some components of cigarette smoke.
August 1987, Life sciences,
J S Fowler, and N D Volkow, and G J Wang, and N Pappas, and J Logan, and R MacGregor, and D Alexoff, and A P Wolf, and D Warner, and R Cilento, and I Zezulkova
Inhibition of brain monoamine oxidase by adducts of 1,2,3,4-tetrahydroisoquinoline with components of cigarette smoke.
January 1997, Life sciences,
J S Fowler, and N D Volkow, and G J Wang, and N Pappas, and J Logan, and R MacGregor, and D Alexoff, and A P Wolf, and D Warner, and R Cilento, and I Zezulkova
Monoamine oxidase B (MAO-B) inhibition by active principles from Uncaria rhynchophylla.
August 2005, Journal of ethnopharmacology,
J S Fowler, and N D Volkow, and G J Wang, and N Pappas, and J Logan, and R MacGregor, and D Alexoff, and A P Wolf, and D Warner, and R Cilento, and I Zezulkova
Monoamine oxidase (MAO) inhibition--a therapeutic adjunct.
April 1967, Medical times,
J S Fowler, and N D Volkow, and G J Wang, and N Pappas, and J Logan, and R MacGregor, and D Alexoff, and A P Wolf, and D Warner, and R Cilento, and I Zezulkova
[Monoamine oxidase (MAO)].
August 1999, Nihon rinsho. Japanese journal of clinical medicine,
J S Fowler, and N D Volkow, and G J Wang, and N Pappas, and J Logan, and R MacGregor, and D Alexoff, and A P Wolf, and D Warner, and R Cilento, and I Zezulkova
Brain monoamine oxidase (MAO) B: a unique neurotoxin and neurotransmitter producing enzyme.
January 1989, Progress in neuro-psychopharmacology & biological psychiatry,
J S Fowler, and N D Volkow, and G J Wang, and N Pappas, and J Logan, and R MacGregor, and D Alexoff, and A P Wolf, and D Warner, and R Cilento, and I Zezulkova
[MONOAMINE OXIDASE INHIBITORS (MAO)].
May 1964, [Sogo rinsho] Clinic all-round,
J S Fowler, and N D Volkow, and G J Wang, and N Pappas, and J Logan, and R MacGregor, and D Alexoff, and A P Wolf, and D Warner, and R Cilento, and I Zezulkova
[Monoamine oxidase (MAO) isozyme].
January 1972, Rinsho byori. The Japanese journal of clinical pathology,
J S Fowler, and N D Volkow, and G J Wang, and N Pappas, and J Logan, and R MacGregor, and D Alexoff, and A P Wolf, and D Warner, and R Cilento, and I Zezulkova
Antiapoptotic actions of monoamine oxidase B inhibitors.
January 1998, Advances in pharmacology (San Diego, Calif.),
Copied contents to your clipboard!